Real-world Study of Secukinumab for Moderate to Severe Hidradenitis Suppurativa
Part of Infections, Skin clinical trials.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have moderate to severe hidradenitis suppurativa (confirmed by your dermatologist)
- You are starting secukinumab treatment within 30 days of enrolling in the study
- You have not previously received secukinumab through any access program
- You are willing to provide written consent and privacy permission
- You are not currently enrolled in another clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well secukinumab (Cosentyx) works in real life for people with moderate-to-severe hidradenitis suppurativa (HS) in Canada. If you're just starting this treatment, researchers want to track your progress and side effects.
This study looks at people with moderate to severe hidradenitis suppurativa (HS) who start treatment with secukinumab early. It aims to see how well the treatment works and how it affects the condition over time.
This study looks at whether secukinumab (a drug used for hidradenitis suppurativa) affects heart health in people who also have high heart risk or heart plaque. You'd receive the standard care with secukinumab and undergo special heart imaging to see how the drug affects your arteries.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.